Concentrations of Credit Risk and Current Expected Credit Losses (Tables)

6 Months Ended

Jun. 30, 2022

Concentrations of Credit Risk and Current Expected Credit Losses

Schedule of concentration of credit risk related to collaborative partners

In November 2011, we began commercialization and distribution of JAKAFI, in April 2020, we began commercialization and distribution of PEMAZYRE, and in October 2021, we began commercialization and distribution of OPZELURA to a number of customers. Our product revenues are concentrated in a number of these customers. The concentration of credit risk related to our JAKAFI, PEMAZYRE and OPZELURA product revenues is as follows:

	Percentage of Total Net				Percentage of Total Net
	Product Revenues for the				Product Revenues for the
	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
Customer A	19	%	19	%	19	%	18	%
Customer B	12	%	13	%	12	%	13	%
Customer C	16	%	18	%	18	%	18	%
Customer D	6	%	10	%	5	%	10	%
Customer E	10	%	12	%	10	%	12	%